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INTRODUCTION
The use of calcineurin inhibitors (CNIs), cyclosporine A (CsA) and tacrolimus has revolutionized solid organ transplantation over the last 30 years (Gaston 2009 ). However, clinical use of CsA is associated with both acute and chronic nephrotoxicity which is a major limiting factor in its use.
While alternative therapeutics have been sought, CNIs remain our most effective and widely used immunosuppressants (Gaston, 2009) . While acute CsA nephrotoxicity is managed clinically through careful monitoring of renal function and appropriate regimen adjustment, the balance between preventing immunologic allograft loss and the management of chronic CNI nephrotoxicity (particularly CsA nephropathy) is still a major issue in renal transplantation (Bestard et al., 2005) . Early diagnosis of nephropathy can greatly improve patient prognosis. However the initial stages of CsA nephropathy are largely asymptomatic making early diagnosis difficult. Therefore identification of novel, early disease indicators is currently a major research focus.
Current diagnostic techniques employed to detect CsA nephropathy are inadequate. The primary method is estimation of glomerular filtration rate (eGFR) (Cockcroft and Gault, 1976) . However this technique is limited since eGFR varies greatly both between patients, and over time within a patient (Kwong et al., 2010) . eGFR is the net result of the complex interaction of multiple factors including age, blood pressure and other diseases. Many of these factors are variable and so compensation can often occur, leading to stabilisation of eGFR, effectively masking early renal functional decline. (Thomas et al., 1998; Clarke and Ryan, 1999; Yang et al., 2002; Ling et al., 2003) . Using this protocol ensured that by 4 weeks of CsA treatment significant nephropathy had developed. The 1 week
CsA group was utilised to examine early toxic effects of CsA before overt histological alterations had manifested. (Ling et al., 2003; Chaaya et al., 2011) . Mice had free access to food and water throughout the experiments.
At the end of each treatment period mice were housed in group metabolism cages for 24 hours for urine collection which was then frozen at - 
Renal function and histology
Renal function was assessed by determination of serum creatinine and urinary protein (proteinuria). Serum creatinine was measured using the Quantichrom™ Creatinine Assay Kit (Cat no. DICT-500, Bioassay systems assay kit), according to the manufacturers protocol. This colorimetric assay is based on the improved Jaffe method. Proteinuria was measured using the Bradford Assay for assessing total protein quantities in a biological sample (Bradford, 1976) . Urine samples were normalised for urinary output. Half a kidney was fixed in neutral buffered formalin, paraffin embedded and sectioned at 5µm. After de-waxing, gross renal histology was examined using standard haematoxylin and eosin (H&E) staining (Sigma-Aldrich). Collagen staining of sections was performed using Masson's Trichrome stain (Sigma-Aldrich). Sections were stained using an automated slide stainer (Leica autostainer XL).
Quantitative Polymerase Chain Reaction (PCR)
Total RNA was isolated using the trizol method from half a kidney stored at -80°C in RNAlater™ (Ambion Cat no. AM7020) according to the manufacturers protocol. 1μg of total RNA was used to synthesis cDNA. A Real-Time PCR
TaqMan assay was used to quantify the relative expression levels of genes of interest and has been described previously (Feighery et al., 2008) . Briefly, cDNA was amplified on the ABI 7900HT Sequence Detection System at default thermal cycling conditions: 2 min @ 50˚C, 10 min @ 95˚C for enzyme activation and then 40 cycles of 15 sec @ 95˚C for denaturation and 1min @ 60˚C for annealing and extension. Results were analysed using the delta Ct method of analysis. Primer sequences for murine TGF-β1 were designed in the Conway Institute genomics core facility and synthesized by Applied Biosystems. Primer specificity was assessed by nBLAST in the NCBI database. Biosystems.
Quantitative Enzyme-linked Immunosorbant Assay (ELISA)
A TGF-β1 ELISA was used to determine the effect CsA had on urinary TGF-β1 protein levels. This was done according to the manufacturing company's (Cat no. DB100B, R&D systems) protocol. The specificity and sensitivity of the assay was assessed using 5ng of TGF-β1 as a positive control and sterile water as a negative control.
Western blot analysis
Total kidney protein was isolated using the RIPA buffer method (Sigma-Alridch, R0278) from renal homogenates according to the manufacturers protocol. The SDS-PAGE procedure used was that of Laemmli (Laemmli, 1970) . Expression levels of renal proteins following CsA treatment was determined by Western blot and has been described previously (McMorrow et al., 2005; Slattery et al., 2005; Feighery et al., 2008) . Proteins of interest were detected using the following antibodies according to the manufacturers protocol, mouse monoclonal anti-α-SMA antibody (A2547 Sigma-Aldrich), mouse monoclonal anti-Cadherin 1 (CDH-1) antibody (61081, BD biosciences) or rabbit anti-CTGF polyclonal antibody (A gift from Dr. John Crean, UCD Conway Institute). In urinary western blots colloidal coomassie blue stain (Sigma-Aldrich, B8522) which stains all proteins within a polyacrylamide gel was used as a loading control to ensure equal loading of proteins.
2-dimensional gel electrophoresis (2-DE)
Identification of novel proteins in urine that may be involved in CsA induced renal fibrosis was assessed using 2DE and mass spectrometry which has been described previously (Feighery et al., 2008) . Briefly, urine samples were prepared for 2-DE by centrifugation at 12000g for 5 min to remove any potential contaminants. The samples were then resuspended in a 1:1 volume of lysis buffer (9.5 M Urea; 2% CHAPS; 0.8% Pharmalyte pH 3-10; 1% DTT).
A C C E P T E D M A N U S C R I P T
Protein quantitation was measured using the Bradford assay prior to first dimension isoelectric focusing (IEF) (Bradford, 1976) . The pooled urine samples were divided into 500µg aliquots for subsequent 2-DE, mass spectrometry and database analysis. This analysis was repeated at least five times.
Confocal microscopy
CDH1 localization was detected by indirect immune-fluorescence using an Alexa-546 conjugated secondary antibody (Invitrogen) (excitation 543nm/ emission 570nm). CDH-1 localization was detected by confocal microscopy (Zeiss LSM 510 Meta confocal microscope using 63x objective lens).
Statistical Analysis
Statistical analyses were performed using GraphPad Prism 4.0. Data was analysed by one-way analysis of variance (ANOVA) and multiple comparisons between control and treatment groups were made using the Bonferroni post-test. A student t-test was used for assessing statistical differences between two groups. A probability of 0.05 or less was deemed statistically significant. Results were expressed as the mean ± SEM. The following scheme was used throughout the work; * p<0.05, ** p<0.01, *** p<0.001, compared to time matched control.
RESULTS

Renal functional alterations in CD-1 mice following CsA treatment
Serum creatinine and proteinuria were assessed to determine the effects of CsA on renal function (Table 1) . After 1 week CsA treatment, no significant change in either parameter was detected. After 4 weeks CsA treatment, significant increases in both serum creatinine levels and in urinary protein levels were observed compared to time-matched controls. Taken together these results suggested significant decline in renal function of CsA treated mice after 4 weeks.
Histopathological and gene expression alterations in CD-1 mice
following CsA treatment H&E and Masson trichrome staining of kidney tissue was performed to assess the effect of CsA treatment on renal histology ( Figure 1A ). After 1 week CsA treatment no significant changes to gross renal histology were detectable.
However, after 4 weeks CsA treatment, significant histopathological alterations were observed compared to time-matched controls. These effects were particularly marked in glomerular and tubular compartments. Some renal tubules appeared disorganized, irregular in shape and separated from neighbouring tubules. Masson trichrome staining indicated marked accumulation of collagen within the tubulointerstitium after 4 weeks of CsA administration. Increased interstitial collagen has been observed in other models of TIF (Murphy et al., 1999; Kattla et al., 2008) . The expression of fibroblast markers FSP-1 and α-SMA were assessed ( Figure 1C and D).
Significant increases in FSP-1 mRNA levels were detected at both 1 week and 4 weeks in CsA treated mice compared to time-matched controls. α-SMA protein levels were significantly increased in CsA treated mice at both 1 week and 4 weeks compared to time-matched controls. However, increased α-SMA mRNA levels were only detected after 4 weeks CsA treatment. This may be due to altered protein processing and/or post-translational modifications that may have resulted in increased protein without a detectable change in mRNA.
A C C E P T E D M A N U S C R I P T
Taken together these results provide strong evidence of TIF in CsA treated mice by week 4.
The effect of CsA on mediators of TIF in CD-1 mice
The effects of CsA on TGF-β1, CTGF and BMP-7 in CD-1 mice were assessed as they are known mediators of TIF in other models (Ling et al., 2003; Shihab et al., 2003; Kattla et al., 2008; Veerasamy et al., 2009 ) ( Figure   2 ). CsA treatment caused significant increases in TGF-β1 mRNA levels in whole kidney RNA after 1 week and 4 weeks treatment (Figure 2Ai ). TGF-β1
protein was also significantly upregulated in both whole kidney and urine ( Figure 2Aii , iii). However, in whole kidney protein, increased TGF-β1 was only detected after 4 weeks, whereas urinary TGF-β1 levels were significantly elevated in both 1 and 4 weeks CsA treated groups. The effect of CsA on CTGF mRNA levels in whole kidney RNA were similar to those on TGF-β1 with significant increases detected at both 1 and 4 weeks in the CsA groups ( Figure 2B i) . In contrast however, increased CTGF protein levels were detected in whole kidney at both 1 and 4 weeks but urinary CTGF protein levels were not significantly elevated until week 4 of CsA treatment ( Figure 2B ii and iii). BMP-7 is a negative regulator of fibrosis. A significant reduction in BMP-7 gene expression in whole kidney RNA was detected following 4 week CsA treatment ( Figure 2C ). Together, these findings provide further evidence that TIF is well established in CsA treated CD-1 mice by 4 weeks.
Furthermore, these results indicate that the fibrotic process has initiated by the 1 week time point. Considering these results, it was decided that urine analysis would focus on the one week treatment group since identification of significantly altered proteins at this stage would be more attractive as early nephrotoxicity indicators.
Evaluation of podocin and uromodulin as markers of CsA nephrotoxicity
Previous studies suggest that increased urinary levels of podocin, a slit-diaphragm protein, may be an early marker of glomerular damage in vivo (Sato et al., 2009 ). Therefore we examined podocin in the present model. (also known as Tamm-Horsfall protein) is normally detected at high levels in urine and has been proposed to play a protective role in the kidney (Prajczer et al., 2010) . Urinary uromodulin levels were significantly decreased following 1 week CsA treatment ( Figure 3B Table 2 .
CsA-induced alterations in CDH-1 expression in CD-1 mice
Following proteomic investigation CDH-1 was chosen for further analysis. CDH-1 was of interest as it was the only renal tubule specific marker identified from the proteomic analysis. Since tubular dysfunction is a major mechanistic feature of CsA nephrotoxicity, urinary CDH-1 was of particular interest as a potential early indicator of tubular dysfunction. Since urinary CDH-1 levels were significantly increased, the effect of CsA on CDH-1 whole kidney protein levels was examined to determine whether the alterations in urinary CDH-1 correlated with CDH-1 levels in the kidney.
Significant down-regulation of CDH-1 was observed by Western blotting at both 1 and 4 weeks ( Figure 5A ). This effect was also observed by
A C C E P T E D M A N U S C R I P T
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13 immunofluorescent microscopy where a marked reduction in the number of tubular epithelial cells expressing CDH-1 was observed following CsA treatment (4 weeks) ( Figure 5B ). CDH-1 staining on a 5µM kidney crosssection appeared as punctuate red staining located at the junctions, on the apical sides of the epithelial cells in the tubules. This tubular staining of CDH-1 was markedly decreased following CsA treatment and is indicated by the white arrows.
Discussion
Despite its nephrotoxic side-effects, CsA avoidance regimens result in increased acute rejection and these avoidance strategies have been discarded (Reis, 2010) . Histopathological analysis revealed significant tubular atrophy and interstitial collagen accumulation in CsA treated mice by week 4. Fibroblast accumulation is also a feature of TIF (Qi et al., 2006) and this was reflected by increased levels of FSP-1 and α-SMA protein in whole kidney lysates.
For the purposes of this study putative nephrotoxicity markers were designated as those identified in the literature as having a significant role in nephrotoxicity in a number of in vitro and in vivo models of renal disease.
These included TGF-β1, CTGF and BMP-7 (Zeisberg et al., 2003; Xu et al., 2009 ). The profibrotic cytokine TGF-β1 is a major contributor to TIF and nephropathy (Ling et al., 2003) . Increased TGF-β1 mRNA and protein expression after CsA treatment suggests a role for TGF-β1 in the current model, and this is in agreement with previous studies (Shihab et al., 2003; Shihab et al., 2006; Lloberas et al., 2008) . However, despite some initially promising results in experimental models of CsA nephropathy (Ling et al., 2003; El Chaar et al., 2007) , TGF-β1 blockade has not yet translated into an effective therapeutic strategy in human patients. Both CTGF and BMP-7 are downstream modulators of TGF-β1 signalling (Veerasamy et al., 2009;  A C C E P T E D M A N U S C R I P T of TIF (Ito et al., 1998; Gupta et al., 2000; Yokoi et al., 2002; Wang and Hirschberg, 2003) . In contrast, BMP-7 is anti-fibrotic and is decreased in models of renal fibrosis (Turk et al., 2009) . The effects of CsA on CTGF and BMP-7 in the current study would likely favour the pro-fibrotic response and further underline the establishment of a fibrotic model after 4 weeks CsA treatment.
Combining the functional and histological observations with the results of gene expression studies, we concluded that 4 weeks of CsA treatment was sufficient to induce alterations consistent with CsA nephropathy. Critically, a subset of these effects were detectable by 1 week of CsA treatment suggesting that the mechanisms driving the pathophysiological response were initiating at that early time point. It was therefore determined that the 1 week time point would by the focus of further proteomic analysis of urine to identify potential markers of CsA nephrotoxicity.
In this study significant changes in urinary podocin were observed even after a short CsA treatment period, prior to gross morphological changes and severe nephrotoxicity. This is a significant and promising finding as there is emerging evidence from several experimental models and human diseases that podocyte damage and loss, can contribute to the initiation and progression of renal disease (Macconi et al., 2009; Sato et al., 2009; Wang et al., 2009) . Podocytes are specialized epithelial cells covering the basement membrane of the glomerulus and form the final barrier to serum protein loss.
Podocin, a member of the stomatin family of membrane proteins, is exclusively expressed in the slit diaphragm that connects neighbouring podocytes in the glomerulus (Huber et al., 2001) . The slit diaphragm is a key structure involved in maintaining podocyte integrity. Measurement of urinary podocin along with other podocyte proteins has been proposed as a useful tool for detecting glomerular damage and renal disease development in other settings (Sakairi et al., 2010) , but this study is the first report associating podocin loss with CsA nephrotoxicity.
Uromodulin (Tamm-Horsfall protein) is the most abundant protein in normal urine (Hession et al., 1987) . In the present study decreases urinary Tamm-Horsfall protein levels were detected following 1 week of CsA (Kistler et al., 2009; Prajczer et al., 2010) . Urinary Tamm-Horsfall protein levels have previously been proposed as an indicator of renal function in transplant recipients (Kaden et al., 1994) and the results of this study suggest that urinary uromodulin levels may also be an indicator of CsA nephrotoxicity.
2-DE combined with mass spectrometry is a reliable high-throughput
method which can be used to identify potential markers of toxicity. Using this technique, 15 urinary proteins that were significantly altered by 1 week of CsA treatment were identified (Table 2) . These included Heat shock protein 60 (Hsp60), superoxide dismutase (SOD), apolipoprotein A1, mouse transthyretin and serum albumin precursor. Several isoforms of actin were also detected along with vinculin, another cytoskeletal protein. Further analysis is required to determine the specific roles of these proteins and their usefulness as indicators and/or therapeutic targets in CsA-nephropathy. One protein, CDH-1, was selected for further analysis. CDH-1 was increased in the urine of CsA treated mice with a corresponding decrease in whole kidney protein expression by 1 week of CsA treatment. CDH-1 is a critical epithelial adhesion molecule that is highly expressed along the tubular epithelium.
Urinary loss of CDH-1 suggests breakdown of the tubular junctions likely leading to loss of tubular integrity and function (Slattery et al., 2005) .
Increased urinary CDH-1 has been detected in patients with diabetic nephropathy has been suggested to have clinical diagnostic value in that setting . We propose that urinary CDH-1 may also be an early indicator of CsA nephropathy.
The results from this current study identify a number of novel aspects of CsA nephrotoxicity, highlighting roles for both the tubular epithelium and Framework grant "SysKid", HEALTH-F2-2009-241544. 
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